Compendium of Cancer Genome Aberrations

Changes

HAEM5:Volunteer Assignments and Opportunities (view source)

Revision as of 18:02, 22 March 2024

228 bytes added ,  22 March
no edit summary
Line 1,812: Line 1,812:  
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
−
|[[HAEM5:EBV-positive diffuse large B-cell lymphoma|EBV-positive diffuse large B-cell lymphoma]]||Disease|| || || || || ||GC|| ||
+
|[[HAEM5:EBV-positive diffuse large B-cell lymphoma|EBV-positive diffuse large B-cell lymphoma]]||Disease||Fnu Monika (trainee) + Andrew Siref as mentor
 +
|3/22/24|| ||Pending|| ||GC|| ||
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
Line 2,140: Line 2,141:  
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
−
|[[HAEM5:Autoimmune lymphoproliferative syndrome|Autoimmune lymphoproliferative syndrome]]||Disease|| || || || || ||SK|| ||
+
|[[HAEM5:Autoimmune lymphoproliferative syndrome|Autoimmune lymphoproliferative syndrome]]||Disease||Aviv Oren, MD (trainee), mentor needed
 +
| || || || ||SK|| ||
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
Line 2,154: Line 2,156:  
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
−
|[[HAEM5:T-lymphoblastic leukaemia / lymphoma, NOS|T-lymphoblastic leukaemia / lymphoma, NOS]]||Disease|| || || || || ||HD|| ||
+
|[[HAEM5:T-lymphoblastic leukaemia / lymphoma, NOS|T-lymphoblastic leukaemia / lymphoma, NOS]]||Disease|| || || || || ||SK|| ||
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
Line 2,168: Line 2,170:  
|
 
|
 
|
 
|
−
|HD
+
|SK
 
|
 
|
 
|
 
|
Line 2,204: Line 2,206:  
|
 
|
 
|-
 
|-
−
|[[HAEM5:NK-large granular lymphocytic leukaemia|NK-large granular lymphocytic leukaemia]]||Disease||Michelle Don, MD, MS
+
|[[HAEM5:NK-large granular lymphocytic leukaemia|NK-large granular lymphocytic leukaemia]]||Disease||Hailee St. Louis (trainee);
 +
Michelle Don, MD, MS
 
|3/17/24
 
|3/17/24
 
|6/30/24
 
|6/30/24
Line 2,310: Line 2,313:  
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
−
|[[HAEM5:Indolent T-cell lymphoma of the gastrointestinal tract|Indolent T-cell lymphoma of the gastrointestinal tract]]||Disease||PENDING
+
|[[HAEM5:Indolent T-cell lymphoma of the gastrointestinal tract|Indolent T-cell lymphoma of the gastrointestinal tract]]||Disease||
 
| || || || ||SK|| ||
 
| || || || ||SK|| ||
 
|Indolent T-cell Lymphoproliferative Disorder of the Gastrointestinal Tract
 
|Indolent T-cell Lymphoproliferative Disorder of the Gastrointestinal Tract
Line 2,325: Line 2,328:  
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
−
|[[HAEM5:Enteropathy-associated T-cell lymphoma|Enteropathy-associated T-cell lymphoma]]||Disease||Monica Fnu (trainee), Andrew Siref, MD
+
|[[HAEM5:Enteropathy-associated T-cell lymphoma|Enteropathy-associated T-cell lymphoma]]||Disease||Fnu Monika, MBBS (trainee),  
 +
Andrew Siref, MD
 
|3/20/24
 
|3/20/24
−
| || || ||SK|| ||
+
| ||Pending|| ||SK|| ||
 
|Enteropathy-Associated T-cell Lymphoma
 
|Enteropathy-Associated T-cell Lymphoma
 
|*Derick Okwan-Duodu, MD, PhD *Sumire Kitahara, MD
 
|*Derick Okwan-Duodu, MD, PhD *Sumire Kitahara, MD
Line 2,334: Line 2,338:  
|
 
|
 
|-
 
|-
−
|[[HAEM5:Monomorphic epitheliotropic intestinal T-cell lymphoma|Monomorphic epitheliotropic intestinal T-cell lymphoma]]||Disease||Monica Fnu (trainee), Andrew Siref, MD
+
|[[HAEM5:Monomorphic epitheliotropic intestinal T-cell lymphoma|Monomorphic epitheliotropic intestinal T-cell lymphoma]]||Disease||Fnu Monika, MBBS (trainee),  
 +
Andrew Siref, MD
 
|3/20/24
 
|3/20/24
−
| || || ||SK|| ||
+
| ||Pending|| ||SK|| ||
 
|Monomorphic Epitheliotropic Intestinal T-cell Lymphoma
 
|Monomorphic Epitheliotropic Intestinal T-cell Lymphoma
 
|Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD
 
|Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD
Line 2,343: Line 2,348:  
|
 
|
 
|-
 
|-
−
|[[HAEM5:Intestinal T-cell lymphoma, NOS|Intestinal T-cell lymphoma, NOS]]||Disease||PENDING
+
|[[HAEM5:Intestinal T-cell lymphoma, NOS|Intestinal T-cell lymphoma, NOS]]||Disease||
 
| || || || ||SK|| ||
 
| || || || ||SK|| ||
 
|Intestinal T-cell Lymphoma, Not Otherwise Specified (NOS)
 
|Intestinal T-cell Lymphoma, Not Otherwise Specified (NOS)
Line 2,351: Line 2,356:  
|
 
|
 
|-
 
|-
−
|[[HAEM5:Hepatosplenic T-cell lymphoma|Hepatosplenic T-cell lymphoma]]||Disease||Michelle Don, MD, MS
+
|[[HAEM5:Hepatosplenic T-cell lymphoma|Hepatosplenic T-cell lymphoma]]||Disease||Forough Sargolzaeiaval (trainee);
 +
Michelle Don, MD, MS
 
|3/19/24
 
|3/19/24
 
|6/30/24
 
|6/30/24
Line 2,387: Line 2,393:  
|
 
|
 
|-
 
|-
−
|[[HAEM5:Breast implant-associated anaplastic large cell lymphoma|Breast implant-associated anaplastic large cell lymphoma]]||Disease||PENDING
+
|[[HAEM5:Breast implant-associated anaplastic large cell lymphoma|Breast implant-associated anaplastic large cell lymphoma]]||Disease||
 
| || || || ||SK|| ||
 
| || || || ||SK|| ||
 
|Breast Implant-Associated Anaplastic Large Cell Lymphoma
 
|Breast Implant-Associated Anaplastic Large Cell Lymphoma
Line 2,395: Line 2,401:  
|
 
|
 
|-
 
|-
−
|[[HAEM5:Nodal TFH cell lymphoma, angioimmunoblastic-type|Nodal TFH cell lymphoma, angioimmunoblastic-type]]||Disease||Rachel Burnside updating (prior authors not available)||7/28/2023
+
|[[HAEM5:Nodal TFH cell lymphoma, angioimmunoblastic-type|Nodal TFH cell lymphoma, angioimmunoblastic-type]]||Disease||Rachel Burnside, PhD||7/28/2023
−
| ||Pending|| ||SK|| ||
+
| ||Pending|| ||SK|| ||prior authors not available
 
|Angioimmunoblastic T-cell Lymphoma
 
|Angioimmunoblastic T-cell Lymphoma
 
|Sara Akhavanfard, M.D., Ph.D. and Ruthann Pfau, Ph.D., FACMG
 
|Sara Akhavanfard, M.D., Ph.D. and Ruthann Pfau, Ph.D., FACMG
Line 2,403: Line 2,409:  
|
 
|
 
|-
 
|-
−
|[[HAEM5:Nodal TFH cell lymphoma, follicular-type|Nodal TFH cell lymphoma, follicular-type]]||Disease||Rachel Burnside||7/28/2023
+
|[[HAEM5:Nodal TFH cell lymphoma, follicular-type|Nodal TFH cell lymphoma, follicular-type]]||Disease||Rachel Burnside, PhD||7/28/2023
 
| ||Pending|| ||SK|| ||
 
| ||Pending|| ||SK|| ||
 
|NEW (No Prior)
 
|NEW (No Prior)
Line 2,411: Line 2,417:  
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
−
|[[HAEM5:Nodal TFH cell lymphoma, NOS|Nodal TFH cell lymphoma, NOS]]||Disease||PENDING
+
|[[HAEM5:Nodal TFH cell lymphoma, NOS|Nodal TFH cell lymphoma, NOS]]||Disease||
 
| || || || ||SK|| ||
 
| || || || ||SK|| ||
 
|Nodal Peripheral T-cell Lymphoma with T Follicular Helper Phenotype
 
|Nodal Peripheral T-cell Lymphoma with T Follicular Helper Phenotype
Line 2,426: Line 2,432:  
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
−
|[[HAEM5:EBV-positive nodal T- and NK-cell lymphoma|EBV-positive nodal T- and NK-cell lymphoma]]||Disease|| || || || || ||SK|| ||
+
|[[HAEM5:EBV-positive nodal T- and NK-cell lymphoma|EBV-positive nodal T- and NK-cell lymphoma]]||Disease||Fnu Monika, MBBS (trainee), Andrew Siref, MD||3/22/24|| ||Pending|| ||SK|| ||
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
Line 2,464: Line 2,470:  
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
−
|[[HAEM5:Systemic EBV-positive T-cell lymphoma of childhood|Systemic EBV-positive T-cell lymphoma of childhood]]||Disease||PENDING
+
|[[HAEM5:Systemic EBV-positive T-cell lymphoma of childhood|Systemic EBV-positive T-cell lymphoma of childhood]]||Disease||
−
| || || || ||SK|| ||
+
| || || || ||SK|| ||prior authors not available
 
|Systemic EBV-Positive T-cell Lymphoma of Childhood
 
|Systemic EBV-Positive T-cell Lymphoma of Childhood
 
|Lisa A. Lansdon, PhD and Linda D. Cooley, MD, MBA
 
|Lisa A. Lansdon, PhD and Linda D. Cooley, MD, MBA
Retrieved from "https://ccga.io/index.php/Special:MobileDiff/14387...14394"